Looking to Play Intellia’s Ground-Breaking Gene Therapy?

Intellia Therapeutics (NTLA) CEO John Leonard believes that gene-editing therapy could come to market “very, very soon,” according to an interview on CNBC’s Closing Bell, after news broke that CRISPR-based medicine was recently applied in a systemic delivery to a human in a breakthrough trial. The...